Skip to main content
Home
FULL MENU Close Menu
Home
Home

Neil Osterweil

News

Crizotinib Continues to Produce High Response in ALK+ NSCLC

Author:
Neil Osterweil
Publish date: June 5, 2011

Major Finding: In an ongoing phase I trial, the overall response rate to crizotinib was 61%, and the median duration of response was 48 weeks.Data...

  • Read More

News

Therapy Matched to Tumor Abnormalities Tied to Longer Survival

Author:
Neil Osterweil
Publish date: June 4, 2011

Major Finding: Patients with advanced cancer who had therapy matched to molecular abnormalities in their tumors survived about 4 months longer...

  • Read More

News

Diabetes, Hypoglycemia Could Point to Dementia

Author:
Neil Osterweil
Publish date: May 1, 2011

  • Read More

News

Treatments Few for Alzheimer's, Parkinson's, Lewy Body Dementia

Author:
Neil Osterweil
Publish date: April 14, 2011

Major Finding: In Alzheimer’s disease, antipsychotic efficacy is offset by tolerability and mortality concerns. Antidepressants and dopamine...

  • Read More

News

Treatments Few for Alzheimer's, Parkinson's, Lewy Body Dementia

Author:
Neil Osterweil
Publish date: April 14, 2011

Major Finding: In Alzheimer’s disease, antipsychotic efficacy is offset by tolerability and mortality concerns. Antidepressants and dopamine...

  • Read More

News

Treatments Few for Alzheimer's, Parkinson's, Lewy Body Dementia

Author:
Neil Osterweil
Publish date: April 14, 2011

Major Finding: In Alzheimer’s disease, antipsychotic efficacy is offset by tolerability and mortality concerns. Antidepressants and dopamine...

  • Read More

News

Depression in Elders With Schizophrenia May Moderate

Author:
Neil Osterweil
Publish date: April 13, 2011

  • Read More

News

Depression in Elders With Schizophrenia May Moderate

Author:
Neil Osterweil
Publish date: April 13, 2011

  • Read More

News

Depression in Elders With Schizophrenia May Moderate

Author:
Neil Osterweil
Publish date: April 13, 2011

  • Read More

News

Citalopram Reduces Suicidal Ideation, Depression in Schizophrenia

Author:
Neil Osterweil
Publish date: April 13, 2011

Major Finding: The selective serotonin reuptake inhibitor citalopram is effective for reducing depressive symptoms and suicidal ideation in older...

  • Read More

News

Citalopram Reduces Suicidal Ideation, Depression in Schizophrenia

Author:
Neil Osterweil
Publish date: April 13, 2011

Major Finding: The selective serotonin reuptake inhibitor citalopram is effective for reducing depressive symptoms and suicidal ideation in older...

  • Read More

News

Citalopram Reduces Suicidal Ideation, Depression in Schizophrenia

Author:
Neil Osterweil
Publish date: April 13, 2011

Major Finding: The selective serotonin reuptake inhibitor citalopram is effective for reducing depressive symptoms and suicidal ideation in older...

  • Read More

News

Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment

Author:
Neil Osterweil
Publish date: April 11, 2011

Major Finding: Despite having similar hemoglobin A1c levels, older diabetic patients with dementia were more than twice as likely as cognitively...

  • Read More

News

Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment

Author:
Neil Osterweil
Publish date: April 11, 2011

Major Finding: Despite having similar hemoglobin A1c levels, older diabetic patients with dementia were more than twice as likely as cognitively...

  • Read More

News

Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment

Author:
Neil Osterweil
Publish date: April 11, 2011

Major Finding: Despite having similar hemoglobin A1c levels, older diabetic patients with dementia were more than twice as likely as cognitively...

  • Read More

Pages

  • « first
  • …
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close